Oversigt over landesvar.

Slovenien: In Slovenia, there is no special reimbursement schemes for orphan drugs. If they are reimbursed, they are usually reimbursed 100 % by compulsory health insurnace as are drugs for diabetes, cancer etc.

Norge: Medicines for dangerous contagious illnesses – Schedule 4. A reimbursement system has also been established to ensure that all patients with serious communicable diseases are given adequate treatment without costs to the patient. There is no patient co-payment for these medicines. Medicines used to treat, e.g. HIV/AIDS or tuber-culosis are reimbursed in this category. Also, vaccines against communicable diseases are reimbursed. All medicines with ATC-code J (i.e. antiinfectives for systemic use) or L03A (immunostimulants) are automatically included in this schedule. No further application is necessary to obtain 100% reimbursement. Long-term treatment is not a prerequisite for Schedule 4.

Malta: In Malta all medicines available on the Government Formulary List are provided entirely free of charge. There are no special reimbursement schemes.

Finland: Drugs in the Special Refund Categories. The Higher Special Refund Category consists of 34 diseases that are, according to medical criteria, considered to be serious and chronic and where drug treatment is necessary for the patient and where the drug restores or replaces normal bodily functions. Drugs used to treat diabetes mellitus or malignant diseases are examples of drugs belonging to the Higher Special Refund Category. The purchase or reference price of a medicinal product is reimbursed to the patient in full (100%), including the pharmacy's processing fee. The patient pays a non-reimbursable sum of EUR 3.00 per transaction for each medicinal product in the Higher Special Refund Category. In addition, the patient will also pay any part of the medicine price exceeding the reference price. The Lower Special Refund Category consists of 10 diseases that are, according to medical criteria, considered to be serious and chronic. The most common diseases in this group are hypertension, asthma and coronary heart disease. Seventy-two per cent of the purchase price or reference price (including the pharmacy's processing fee) of a medicinal product belonging to the Lower Special Refund Category is reimbursed to the patient.

Spanien: In Spain, we have a reduced patient contribution fee for chronic diseases medicines included in defined ATC groups. This fee accounts for 10% of the retail price instead of the normal 40%-60% copayment to be fixed from the new regulation (before 40%).

Litauen: 100 % tilskud til livsvigtigt medicin

1. DRUGS USED IN DIABETES "A10"

- 2. Antiandrogens "G03HA01"
- 3. GLYCOGENOLYTIC HORMONES lyf "H04A"
- 4. ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS "L"
- 5. ANTICHOLINERGIC AGENTSlyf "N04A"
- 6. ANTIPSYCHOTICS "N05 A"
- 7. ANTIGLAUCOMA PREPARATIONS AND MIOTICS "S 01 E"

¹ ATC-Groups:

Østrig: In Austria all drugs listed in the EKO (code of reimbursement) are fully reimbursed, except for a co-payment amounting to €5,15 (effective 2012). Patients can be exempted for social reasons or if they suffer from diseases which are communicable and must be reported (M.I.R: morbus infectiosus referendus).

Nederlandene: In the Netherlands all essential/vital/lifesaving drugs are reimbursed. There is no special or more favourable reimbursement then what applies to other drugs. We do have a maximum price system that is based on the prices in Germany, Belgium the UK and France. Furthermore we have a pharmaceutical reimbursement system. These to tools apply to all pharmaceuticals.

Belgien: In general in Belgium, lifesaving, vital drugs are 100% reimbursed.

England: In the UK, the great majority of new prescription medicines are granted automatic full (100%) reimbursement on the NHS. There is a small number on a negative list. There are no special concessions in relation to essential medicines, although sometimes companies will supply unlicensed medicines free of charge.

Island: In Iceland we have three differen general reimbursement rates, depending on disease. A. Group "*", reimbursement rate is 100%.